Prof. Karl-Heinz Krause is founder and scientific advisor at Neurix SA, Geneva (Switzerland). He founded Neurix in 2011 as a spin-off from the University of Geneva. He is a full-time professor at the Department of Pathology and Immunology, Geneva Medical Faculty. He is a trained specialist in internal medicine and infectious diseases and has a joint appointment with the Geneva University Hospitals. His research is centered around redox-related disease mechanisms and innovative molecular therapies. His main fields of research are reactive oxygen species (ROS)-generating NADPH oxidases, as well as stem cell-based therapies and the development of innovative disease models with a particular focus on neurodegeneration. He has also been active in the biotechnology field. He is co-inventor on numerous patents. He has been active for a long time as a scientific counsellor for the Swiss National Science Foundation. He is an elected member of the Swiss Academy of Medical Sciences, and the American Society for Clinical Investigation.
Prof. Karl-Heinz Krause is founder and scientific advisor at Neurix SA, Geneva (Switzerland). He founded Neurix in 2011 as a spin-off from the University of Geneva. He is a full-time professor at the Department of Pathology and Immunology, Geneva Medical Faculty. He is a trained specialist in internal medicine and infectious diseases and has a joint appointment with the Geneva University Hospitals. His research is centered around redox-related disease mechanisms and innovative molecular therapies. His main fields of research are reactive oxygen species (ROS)-generating NADPH oxidases, as well as stem cell-based therapies and the development of innovative disease models with a particular focus on neurodegeneration. He has also been active in the biotechnology field. He is co-inventor on numerous patents. He has been active for a long time as a scientific counsellor for the Swiss National Science Foundation. He is an elected member of the Swiss Academy of Medical Sciences, and the American Society for Clinical Investigation.